Search Results

with metastatic disease at the time of initial presentation has been observed. 2 This alarming trend is correlated with increasing mortality from anal cancer over the same time period, especially in the Southeastern and Midwestern regions of the United

Anal cancer diagnoses have increased over the past decade. In 2023, an estimated 9,760 new cases of anal cancer will be diagnosed in the United States, with 1,870 estimated deaths. 1 Since its advent in the 1970s, definitive chemoradiotherapy

Techniques for the treatment of anal cancer have developed in parallel with technologic advances in radiation therapy (RT). Combined chemotherapy and RT has replaced radical surgical resection as the cornerstone of treatment for anal malignancies

The standard of care for locally advanced anal cancer is definitive pelvic chemoradiotherapy (CRT). 1 – 5 In the metastatic setting, chemotherapy (cisplatin/5-FU, carboplatin/paclitaxel, or FOLFOX) is considered the standard of care, and the

burden of $112 million. The investigators point out that although the economic impact of anal cancer is small compared with the overall cost of cancer care in the United States, the overall financial burden of SCCA is considerable, given that it

anal cancer. However, treatment failure is frequent in patients with bulky primary tumors and regional lymphadenopathy. To improve the efficacy of chemoradiation, several approaches have been investigated, including changing mitomycin-based chemotherapy

) is the first randomized phase II prospective study to compare 2 chemotherapy doublets, 5-FU/cisplatin versus carboplatin/paclitaxel, in patients with treatment-naïve metastatic anal cancer; results are expected to be reported in 2018. Because there

estimated 8,580 new cases (2,960 men and 5,620 women) of anal cancer involving the anus, anal canal, or anorectum will occur in the United States in 2018, accounting for approximately 2.7% of digestive system cancers. 1 It has been estimated that 1

whose first cancer was a primary colorectal, pancreatic, gastric, hepatic/biliary, esophageal, or anal cancer during 2004 through 2013. SEER-Medicare is a large dataset maintained by the NCI that details inpatient and outpatient medical claims from

recommendation is based on any level of evidence but reflects major disagreement. Overview An estimated 5290 new cases (2100 men and 3190 women) of anal cancer (involving the anus, anal canal, or anorectum) will occur in the United States in 2009